BACKGROUND: Given to the abundant incidence of malnutrition in HIV(+) patients and its effect on progress of AIDS disease, several studies have recommended supplementation therapy (such as Selenium, Levamisole, Zinc). METHODS: This clinical trial was prefunded on patient's with HIV + in Behavior Diseases Consulting Center, Kermanshah, Iran 2006-2007. One hundred-seventy eight out of all patients with CD4 1ess than 350 cell/mm(3) who did not receive antiretroviral drugs were in this study. They were divided into four groups: the first group received 200 micg selenium per day, the second group received levamisole 50 mg every other day, and third group received both two drugs. The fourth group was the control group. All four groups were studied for six months. Patients' baseline CD4 and other data were recorded in a form. CD4 was rechecked after six months and collected values were compared with basic values. CD4 changes were compared among all groups, either. RESULTS:One hundred-seventy eight patients initiated treatment and 108 cooperated in the 6-month follow up assessment. Niuety-two (85%) were males and 15% were female. CD4 decreased in control group and Levamisole group during the study which was significant, but 13 units increase was seen in Selenium-Levamisole group. CD4 count decreased 36 units in Selenium group. Comparing CD4 count change among 4 study groups showed that only CD4 change between Selenium-Levamisole group and control group was significant. CONCLUSION: Regarding to collected results, Selenium-Levamisole supplementation can be used as a supplementation therapy besides antiretroviral therapies.
RCT Entities:
BACKGROUND: Given to the abundant incidence of malnutrition in HIV(+) patients and its effect on progress of AIDS disease, several studies have recommended supplementation therapy (such as Selenium, Levamisole, Zinc). METHODS: This clinical trial was prefunded on patient's with HIV + in Behavior Diseases Consulting Center, Kermanshah, Iran 2006-2007. One hundred-seventy eight out of all patients with CD4 1ess than 350 cell/mm(3) who did not receive antiretroviral drugs were in this study. They were divided into four groups: the first group received 200 micg selenium per day, the second group received levamisole 50 mg every other day, and third group received both two drugs. The fourth group was the control group. All four groups were studied for six months. Patients' baseline CD4 and other data were recorded in a form. CD4 was rechecked after six months and collected values were compared with basic values. CD4 changes were compared among all groups, either. RESULTS: One hundred-seventy eight patients initiated treatment and 108 cooperated in the 6-month follow up assessment. Niuety-two (85%) were males and 15% were female. CD4 decreased in control group and Levamisole group during the study which was significant, but 13 units increase was seen in Selenium-Levamisole group. CD4 count decreased 36 units in Selenium group. Comparing CD4 count change among 4 study groups showed that only CD4 change between Selenium-Levamisole group and control group was significant. CONCLUSION: Regarding to collected results, Selenium-Levamisole supplementation can be used as a supplementation therapy besides antiretroviral therapies.
Authors: Barry E Hurwitz; Johanna R Klaus; Maria M Llabre; Alex Gonzalez; Peter J Lawrence; Kevin J Maher; Jeffrey M Greeson; Marianna K Baum; Gail Shor-Posner; Jay S Skyler; Neil Schneiderman Journal: Arch Intern Med Date: 2007-01-22
Authors: Roland Kupka; Gernard I Msamanga; Donna Spiegelman; Steve Morris; Ferdinand Mugusi; David J Hunter; Wafaie W Fawzi Journal: J Nutr Date: 2004-10 Impact factor: 4.798
Authors: Mehdi Nouarie; Akram Pourshams; Farin Kamangar; Masood Sotoudeh; Mohammad Hossein Derakhshan; Mohammad Reza Akbari; Hafez Fakheri; Mohammad Javad Zahedi; Kathleen Caldwell; Christian C Abnet; Philip R Taylor; Reza Malekzadeh; Sanford M Dawsey Journal: World J Gastroenterol Date: 2004-09-01 Impact factor: 5.742